Myocardial Fibrosis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Myocardial Fibrosis – Pipeline Review, H2 2017’, provides an overview of the Myocardial Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis

The report reviews pipeline therapeutics for Myocardial Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myocardial Fibrosis therapeutics and enlists all their major and minor projects

The report assesses Myocardial Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myocardial Fibrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myocardial Fibrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myocardial Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Daewoong Pharmaceutical Co Ltd

Evotec AG

Galectin Therapeutics Inc

Invivosciences Inc

Lead Discovery Center GmbH

MandalMed Inc

Merck & Co Inc

Miragen Therapeutics Inc

Palatin Technologies Inc

ProMetic Life Sciences Inc

Sarfez Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Myocardial Fibrosis - Overview 7

Myocardial Fibrosis - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Myocardial Fibrosis - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Myocardial Fibrosis - Companies Involved in Therapeutics Development 21

Daewoong Pharmaceutical Co Ltd 21

Evotec AG 21

Galectin Therapeutics Inc 22

Invivosciences Inc 22

Lead Discovery Center GmbH 22

MandalMed Inc 23

Merck & Co Inc 23

Miragen Therapeutics Inc 24

Palatin Technologies Inc 24

ProMetic Life Sciences Inc 25

Sarfez Pharmaceuticals Inc 25

TRACON Pharmaceuticals Inc 26

Myocardial Fibrosis - Drug Profiles 27

BMP-7 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

carotuximab - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Drugs for Tissue Fibrosis - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

DWN-10290 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

GRMD-02 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

MRG-201 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

NM-922 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

PBI-4050 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

PL-5028 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

PN1-Ab - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

SP-20102 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

TPI-2049 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

TRC-205 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

VB-0004 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Myocardial Fibrosis - Dormant Projects 81

Myocardial Fibrosis - Product Development Milestones 82

Featured News & Press Releases 82

Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe 82

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 82

Appendix 84

Methodology 84

Coverage 84

Secondary Research 84

Primary Research 84

Expert Panel Validation 84

Contact Us 84

Disclaimer 85

List of Tables

List of Tables

Number of Products under Development for Myocardial Fibrosis, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products under Development by Universities/Institutes, H2 2017 10

Products under Development by Companies, H2 2017 11

Products under Development by Universities/Institutes, H2 2017 12

Number of Products by Stage and Target, H2 2017 14

Number of Products by Stage and Mechanism of Action, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Myocardial Fibrosis – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 21

Myocardial Fibrosis – Pipeline by Evotec AG, H2 2017 22

Myocardial Fibrosis – Pipeline by Galectin Therapeutics Inc, H2 2017 22

Myocardial Fibrosis – Pipeline by Invivosciences Inc, H2 2017 22

Myocardial Fibrosis – Pipeline by Lead Discovery Center GmbH, H2 2017 23

Myocardial Fibrosis – Pipeline by MandalMed Inc, H2 2017 23

Myocardial Fibrosis – Pipeline by Merck & Co Inc, H2 2017 24

Myocardial Fibrosis – Pipeline by Miragen Therapeutics Inc, H2 2017 24

Myocardial Fibrosis – Pipeline by Palatin Technologies Inc, H2 2017 25

Myocardial Fibrosis – Pipeline by ProMetic Life Sciences Inc, H2 2017 25

Myocardial Fibrosis – Pipeline by Sarfez Pharmaceuticals Inc, H2 2017 25

Myocardial Fibrosis – Pipeline by TRACON Pharmaceuticals Inc, H2 2017 26

Myocardial Fibrosis – Dormant Projects, H2 2017 81

List of Figures

List of Figures

Number of Products under Development for Myocardial Fibrosis, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products by Top 10 Targets, H2 2017 13

Number of Products by Stage and Top 10 Targets, H2 2017 13

Number of Products by Top 10 Mechanism of Actions, H2 2017 15

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and Routes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports